About ReBEC

The Brazilian Clinical Trials Registry (ReBEC) is an open-access virtual platform for registering experimental and non-experimental studies involving human beings conducted in Brazilian territory by Brazilian and foreign researchers. ReBEC is a joint project of the Ministry of Health (DECIT/MS), the Pan American Health Organization (PAHO), and the Oswaldo Cruz Foundation (FIOCRUZ). The Executive Committee of ReBEC is composed of the aforementioned institutions and the National Health Surveillance Agency (ANVISA). ReBEC is an important source of information for patients, healthcare professionals, researchers, companies, and research centers. Its support services feature generative artificial intelligence ReBEC@, the first artificial intelligence for clinical trial registration in the world. Learn more

Everything you need to know about ReBEC

Click to access the hotsite

Click to download the PDF version

Instructions for the Registrant

We recommend reading the Registrant's Manual.

1 - Register or log in and fill out the forms normally in Portuguese and English.
For English, if you experience any difficulty, use Google Translate
(or another free translation tool).
2 - Attach the mandatory ethics committee documentation and submit the form.
3 - Save the support number in your WhatsApp contacts. Send a message with your name and username.
It is not necessary or recommended to send your password. 
4 - A reviewer will respond to you. Choose your preferred communication mode:
chat, audio recordings, or scheduled voice call.
5 - Your form will be reviewed in both languages. Follow further instructions to complete approval.

Clinical Research Volunteer

Would you like to become a volunteer in a clinical trial registered in ReBEC?

Access our FAQ to find out how.

11/10/2026  |  Joanne S. Eglovitch  |  RAPS

https://www.raps.org/resource/fda-commissioner-touts-strong-interest-in-early-stage-trial-pilot.html 

Acting US Food and Drug Administration (FDA) Commissioner Kyle Diamantas said there is significant public interest in its recently announced Expedited Investigational New Drug (IND) pilot at the Friends of Cancer Research (FOCR) annual meeting on Tuesday.

Diamantas said the agency has received more than 100 applications and will select six to eight sponsors to participate in the pilot. The participants will be chosen next month, he said.

Both Diamantas and National Cancer Institute (NCI) Director Anthony Letai discussed some of the efforts being made to make early-stage US trials more competitive with countries such as China and Australia and said they are looking forward to working together as partners in Operation TrialBlazer.

The expedited IND pilot is part of Operation TrialBlazer, which was launched in mid-June and features a series of measures designed to speed up drug development from the IND stage to late-stage clinical trials. In the Expedited IND pilot, qualified external institutions will collaborate with sponsors to develop and review protocols for first-in-human (FIH) clinical trials intended for IND submissions to the FDA. (RELATED: HHS and FDA propose clinical trial reforms to expedite drug development, Regulatory Focus 23 June 2026)

Through these programs, FDA and NCI will be working together to streamline clinical research. FDA’s part in the effort is to accelerate early-stage, first-in-human clinical trials and to streamline IND applications while NCI’s role is to collaborate with cancer centers and researchers to streamline clinical trial activation timelines and improve patient enrollment in cancer studies.

11/11/2026  |  Doherty Institute

https://www.doherty.edu.au/articles/from-immune-discovery-to-clinical-trial-the-journey-of-a-covid-19-antibody/ 

How a promising antibody discovered in a person who recovered from COVID-19 progressed from the laboratory to a first-in-human clinical trial.

The COVID-19 pandemic highlighted the need for treatments that can be rapidly developed against emerging infectious diseases. One promising approach is the use of monoclonal antibodies, laboratory-made versions of the body’s natural immune defences that can help prevent or treat viral infections. Researchers from the University of Melbourne, WEHI and collaborating institutions spent five years developing one such antibody, PDI204, taking it from discovery in a person who recovered from COVID-19 through to a Phase I clinical trial in healthy volunteers. While the virus continued to evolve, the project provides valuable lessons for developing antibody therapies against future pandemic threats.

Finding the right antibody: learning from natural immunity
The journey began at the start of the pandemic, when a team of researchers at the University of Melbourne – including Professor Stephen Kent, Associate Professor Adam Wheatley, Associate Professor Jennifer Juno, and Dr Wen Shi Lee – studied a cohort of people who had recovered from COVID-19. After infection with SARS-CoV-2, the virus that causes COVID-19, a person’s B cells keep memory of the virus and can make antibodies against it. The team isolated these memory B cells from people who had recovered from COVID-19 and created a library of antibodies that could be used as potential treatments for SARS-CoV-2.

From a promising candidate to an antiviral treatment
Finding an antibody…

11/10/2026  |  Moe Alsumidaie  |  The Clinical Trial Vanguard

https://www.clinicaltrialvanguard.com/clinical-bellwether/the-1m-trial-is-real-so-is-the-question-it-cant-answer/ 

Meri Beckwith opened her post with a direct challenge: “A lot of the skepticism about AI x Bio boils down to ‘clinical trials are the expensive part and AI can’t help there.'” Then she dropped the number. Lindus Health ran an end-to-end, randomized Phase 2a drug trial in neurology for a total, all-in cost of $1 million, an order of magnitude below benchmarked comparables. The clinical trials community noticed. And then, almost immediately, it split.

One faction read the number as proof. The other read it as a provocation dressed up as evidence.

Both are right, which is what makes this moment worth examining carefully rather than celebrating or dismissing.

What One Million Dollars Actually Proves
The Lindus figure is real, and it deserves credit on its own terms. Getting a randomized controlled Phase 2a trial across the finish line for $1 million is not a rounding error or a semantic trick. For context, Phase 2 trials typically consume tens of millions of dollars in direct costs before a single interim analysis is unblinded. If Lindus genuinely compressed that by a factor of ten through AI-assisted site selection, protocol optimization, remote data capture, and automated monitoring, that is an operational achievement worth scrutinizing in detail.

But scrutiny is precisely what is missing from the current conversation.

The neurology indication is unnamed. The sponsor compound is unnamed. The endpoint design, the patient population size, the duration, the regulatory pathway, all absent from the public claim. That silence does not invalidate the…

11/10/2026 | Mayo Clinic | Newswise

https://www.newswise.com/articles/especialista-da-mayo-clinic-destaca-pesquisas-que-ampliam-as-op-es-de-tratamento-para-pacientes-com-c-ncer-de-bexiga-e-rim 

Cancers of the reproductive and urinary organs—known as genitourinary cancers—affect millions of people worldwide each year. Yousef Zakharia, M.D., a medical oncologist at Mayo Clinic, leads clinical research aimed at improving treatment outcomes for patients with kidney, bladder, and prostate cancer.

“We have made significant progress in cancer therapies,” says Dr. Zakharia, head of the Genitourinary Tumor Group at the Mayo Clinic Comprehensive Cancer Center. “There is still more work to be done, especially for patients whose disease stops responding to standard therapies. Clinical trials help us expand options and advance the field.”

Expanding treatment options for bladder cancer

For many years, cisplatin-based chemotherapy was the primary treatment for bladder cancer. Recently, researchers have identified newer therapeutic options that improve outcomes and are generally well-tolerated, including enfortumab vedotin—an antibody-drug conjugate—and the immunotherapy drug pembrolizumab.

Initially approved by the U.S. Food and Drug Administration for advanced disease, this combination is now being evaluated for use prior to surgery in patients with localized cancer—meaning the cancer has not spread to distant organs. Dr. Zakharia is a co-author of an international study examining this approach in patients with muscle-invasive bladder cancer—a condition where the cancer has grown into the bladder wall and typically requires surgery.

Based on the study’s findings, Dr. Zakharia…

11/10/2026 | Octávio Marques Pontes Neto | Jornal da USP

https://jornal.usp.br/radio-usp/pesquisa-brasileira-mostra-que-controle-rigoroso-da-pressao-arterial-reduz-risco-de-novo-avc/ 

A study involving over 4,300 patients, published in one of the world’s leading medical journals, indicates a 21% reduction in the risk of serious cardiovascular complications.

An important piece of Brazilian research, the "Optimal-Stroke" study, has just been published in the *New England Journal of Medicine*—one of the most prestigious medical journals globally. The study was coordinated by the Hospital Israelita Albert Einstein, with participation and funding from the Brazilian Ministry of Health (via the Proadi-SUS program) and researchers from USP (University of São Paulo) in Ribeirão Preto.

This represents an extraordinary achievement for Brazilian clinical research. The Optimal-Stroke study followed more than 4,300 patients—all of whom had previously experienced an ischemic stroke or a transient ischemic attack—over a period of approximately four years.

The core question was whether stricter blood pressure control could lower the risk of subsequent cardiovascular events. Half of the participants received treatment aimed at keeping their systolic (top) blood pressure below 120 mmHg, while the other half followed the conventional target of below 140 mmHg.

The study was coordinated by Brazilian researchers—led by Dr. Gisele Sampaio Silva and Dr. Otavio Berwanger—and involved institutions from various regions across the country, including our own team from USP in Ribeirão Preto. Support from Proadi-SUS—a partnership between the Ministry of Health and several centers of medical excellence—was essential…